The Australia plasma fractionation market was valued at USD 755.00 Million in 2025 and is expected to grow at a CAGR of 6.10%, reaching USD 1364.90 Million by 2035. The market growth is driven by the growing demand for plasma-derived therapies such as immunoglobulins and clotting factors. Increasing awareness of rare blood disorders and advancements in plasma processing technologies are expected to enhance treatment accessibility. Expanding healthcare infrastructure and government support for plasma collection initiatives are also projected to support market growth in the forecast period.
Base Year
Historical Period
Forecast Period
According to the Australian Institute of Health and Welfare, the rising cancer burden, with cases projected to surpass 200,000 by 2034, is driving demand for plasma-derived therapies, positively impacting growth in the plasma fractionation market.
In February 2025, IPFA partnered with AATM to improve plasma-derived medicine access in Asia. This collaboration strengthens plasma collection and fractionation expertise, which is expected to drive growth in the market.
The market is witnessing steady growth, driven by increasing plasma demand and enhanced production capacities. Key players’ investments in advanced technologies and strategic expansions are significantly boosting market development.
Compound Annual Growth Rate
6.1%
Value in USD Million
2026-2035
*this image is indicative*
Plasma fractionation is a critical process in biotechnology that isolates and purifies proteins from human blood plasma. These proteins, such as immunoglobulins, albumin, and clotting factors, are essential for treating various medical conditions, including immune deficiencies and bleeding disorders. The process involves techniques like cryoprecipitation and chromatography to separate and concentrate these valuable therapeutic proteins. In Australia, the market is experiencing significant growth due to rising demand for plasma-derived therapies and technological advancements in blood plasma processing. The market is poised to reach USD 1364.90 Million by 2035, driven by increasing healthcare investments, an aging population, and expanding production capabilities of key players.
Rising Arthritis Prevalence to Drive the Growth in the Market
The increasing prevalence of arthritis in Australia is a key driver for the plasma fractionation market. According to the Australian Institute of Health and Welfare, around 3.7 million Australians, representing 15% of the population, were living with arthritis in 2023. Musculoskeletal conditions contributed to 13% of the total disease burden, accounting for approximately 723,000 disability-adjusted life years (DALY). The rising demand for plasma-derived therapies, such as immunoglobulins and clotting factors, for the treatment and management of arthritis and related comorbidities is expected to boost market growth. This trend is projected to significantly enhance the market’s value over the coming years.
The market is experiencing multiple trends, including significant advancements in plasma fractionation technologies and the development of state-of-the-art plasma processing facilities.
Rising Advancements in Plasma Fractionation Technologies to Boost the Market Demand
The market is witnessing a notable trend toward the adoption of innovative and highly efficient plasma fractionation technologies. In July 2025, Aegros announced the upcoming completion of its state-of-the-art Haemafrac® Plasma Fractionation facility in Macquarie Park, designed to produce Plasma Derived Medicinal Products (PDMPs), including Immunoglobulin, Hyperimmune Globulins, and Albumin. Utilizing the advanced Tangential Flow Electrophoresis process, the facility promises enhanced production efficiency, superior product safety, and environmental benefits. This shift toward locally manufactured, high-quality plasma products is expected to improve patient access and support market expansion. The adoption of such cutting-edge fractionation methods is likely to drive sustained growth and strengthen Australia’s position in the global plasma therapeutics market.
Advanced Plasma Processing Facilities Driving Growth in Australia Plasma Fractionation Market
The adoption of advanced plasma processing technologies is a significant trend in the market. Facilities integrating automation, robotics, and digital twin technology are improving efficiency, safety, and production capacity. For example, in May 2025, CSL Behring’s Broadmeadows facility in Victoria was recognized as the International Society for Pharmaceutical Engineering (ISPE) 2025 Facility of the Year in the Pharma 4.0 category. The site, now the largest plasma fractionation plant globally, has increased Australia’s plasma processing capacity ninefold. Such technological advancements and operational efficiencies are expected to enhance the market’s ability to meet rising global demand, ultimately boosting overall market growth in the coming years.
Neurology- Based Application Segment Set to Lead Market
The market encompasses multiple therapeutic applications, including neurology, hematology, oncology, immunology, pulmonology, and others. Among these, neurology is poised to take the lead as the fastest-growing segment, driven by the increasing incidence of neurodegenerative disorders such as Parkinson’s disease. According to Parkinson's Australia, Parkinson's incidence rates increase by 4% per year in Australia, affecting approximately 50 new individuals daily and placing a burden of over USD 10 billion annually on healthcare systems. Parkinson's is the fastest-growing neurological condition globally, with an estimated 10 million people affected, according to the World Health Organization. Rising awareness, advancements in treatment options, and a growing patient population contribute to heightened demand. This segment is expected to remain the primary growth driver, reflecting the critical focus on neurological healthcare solutions.
The key features of the market report comprise funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
CSL is the cornerstone of Australia’s plasma fractionation industry. Through CSL Behring Australia, it operates the only domestic fractionation facility in Broadmeadows, Victoria, under the National Fractionation Agreement running until 2026, processing around 13 types of plasma-derived therapies—from immunoglobulins to clotting factors—using plasma donated by Australians. In December 2022, CSL launched a state-of-the-art, AUD 900 million facility that boosted processing capacity ninefold to approximately 9–10 million plasma-equivalent liters annually and has since earned global accolades for its robotics-driven, Pharma 4.0 design.
Grifols Australia, founded in 1990, serves as the regional arm for this Spanish global plasma company, operating from Melbourne. While Grifols does not fractionate plasma domestically, it imports and distributes a range of plasma-derived products and transfusion reagents to Australian clinical labs, hospitals, and blood services, backed by ISO certification and TGA licensing. Grifols is also a contracted supplier of imported immunoglobulin products under Australia’s national supply agreements.
Takeda contributes significantly as an importer of critical plasma-derived therapies. It is a supplier under national contracts delivering imported immunoglobulins and other plasma-based products. Worldwide, Takeda accounts for about 19–21% of the global plasma fractionation market, supported by its extensive global collection network and subcontracting arrangements with organizations such as Sanquin Blood Supply. In Australia, Takeda’s local presence reflects its broader global market strength and reach into plasma-derived care.
Kedrion, headquartered in Italy, is a smaller-scale global plasma-derived therapeutics provider (holding roughly 2–4% global market share in 2022). Kedrion’s global supply network means that its products, typically fractionated from European or North American plasma, are imported into Australia to supplement domestic supply, especially for niche or specialized therapies.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Other key players in the market include LFB S.A., Adma Biologics, Inc., and Sanquin.
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Product
Market Breakup by Method
Market Breakup by Application
Market Breakup by End User
Upto 15% Off
USD
$1999 $1799
$3099 $2789
$4599 $3909
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2025 |
| Historical Period | 2019-2025 |
| Forecast Period | 2026-2035 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Product |
|
| Breakup by Method |
|
| Breakup by Application |
|
| Breakup by End User |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Datasheet
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share